Fol­low­ing an al­most year­long wait, FDA ap­proves Ax­some's rapid-act­ing de­pres­sion drug

Af­ter a near­ly 365-day de­lay, Ax­some Ther­a­peu­tics has se­cured its first drug ap­proval with an FDA green light for Au­veli­ty as a treat­ment for adults with ma­jor de­pres­sive dis­or­der.

The biotech is keep­ing shy on the pric­ing for now and, on an in­vestor call, CEO Her­riot Tabuteau at­trib­uted the FDA’s year­long de­lay main­ly to the Covid-19 pan­dem­ic. The rapid-act­ing NM­DA re­cep­tor an­tag­o­nist is not a sched­uled drug un­der the DEA, the CEO con­firmed on the call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER